Bobby White, PAC
03/08/21

Bobby Lee White, MPAS, PA-C

109 Bridge Street, Suite 300, Danville, Virginia 24541
(434)793-4711 (Office)

EDUCATION

Master of Physician Assistant Studies (Orthopedics) (May 2005)
University of Nebraska Medical Center
Omaha, Nebraska

Bachelor of Science, Medical Science (Physician Assistant studies) (May 2000)
Alderson-Broaddus College
Philippi, West Virginia

Bachelor of Science, Biology (May 1997)
Hampden-Sydney College
Hampden-Sydney, Virginia

ACADEMIC HONORS

Alderson-Broaddus College PA Program (Philippi, WV)
Dean's List (3 Semesters)

Hampden-Sydney College (Hampden-Sydney, VA)
Academic Old Dominion Conference Baseball Team (1995, 1996)
Chi Beta Phi National Scientific Fraternity (1996, 1997)
Omicron Delta Kappa National Leadership Fraternity (1997)
USAA All-American Scholar (1997)
Leadership Merit Scholar (1993-1997)
Columbia/HCA VA Scholarship Recipient (1997)
Dean's List (4 Semesters)

EMPLOYMENT BACKGROUND

Spectrum Medical, Inc. (July 1, 2000 – present)
(formerly Danville Orthopedic Clinic, Inc.)
Danville, VA
Position: Physician Assistant
Responsibilities: See Attached Sheet

(Also assisted Jonathan Krome, MD with all Sports Medicine duties, including coverage of George Washington High School football games, Averett University football games, and the Danville Braves (Rookie League affiliate of the Atlanta Braves) baseball games.)

Danville Regional Medical Center (1995 – 1998)
Danville, VA
Position: Emergency Department Technician
Responsibilities: Phlebotomy, assisting in suturing, setting up sterile trays, application of splints, performing EKG's, transporting patients to x-ray and patient care units, assisting in all trauma and cardiac codes, performing urethral catheterizations.

MEMBERSHIPS

American Academy of PA's
Virginia Academy of PA's

VOLUNTEER EXPERIENCE

YMCA Youth Basketball Coach (Danville, VA)	(2001, 2002)
Brosville Youth Baseball Coach (Axton, VA)	(2001)
Alderson-Broaddus College Assistant Baseball Coach (Philippi, WV)	(1999)
Prince Edward County Volunteer Rescue Squad (Farmville, VA)	(1995 - 1997)
Danville Regional Medical Center	(1995)
Hampden-Sydney College Athletic Department (Hampden-Sydney,VA)	(1994 - 1997)
Danville Orthopedic Clinic (Danville, VA)	(1994)

HOBBIES/ACTIVITIES

Basketball, softball, lifting weights/exercising, deejaying

CLINICAL TRIAL EXPERIENCE

A Phase 3, 14-Day, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Multicenter Study of the Efficacy and Safety of XXX in subjects with pain due to Acute Back Muscle Spasm. (2020-Present). Role: Sub Investigator.

A phase 3 Prospective, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of XXX in in patients with osteoarthritis of the knee.(2020-Present) Role: Sub Investigator

Phase 2, Randomized, Double-Blind, Placebo Controlled study of the safety and efficacy of XXX for the treatment of adhesive Capsulitis of the Shoulder (2020-Present.) Role: Sub-Investigator

A Randomized, Double-Blind, Placebo-Controlled, Multi-center Pilot Study of a Single Injection XXX Combined with YYY to Provide Symptomatic Relief of OA of the Knee. Phase 2.(2020-Present) Role: Sub Investigator

A Randomized, Double-Blind, Placebo controlled, 2-injection, 52 week study to evaluate the efficacy and safety of Intra-articular injections of XXX in subjects with chronic, Moderate-to Severe osteoarthritis knee pain. (Jan 2019-2021). Role: Sub Investigator

A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women with Osteoporosis to Evaluate the Non-inferiority of subjects administered XXX via auto injector/pen vs. Healthcare provider administered XXX via prefilled syringe. (Jan 2018-2019). Role: Sub-Investigator.

A Phase 4, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of XXX in combination with XOI compared with XOI alone, in subjects with Gout and Estimated Creatinine Clearance 30 to <60 mL/min who have not achieved target serum uric acid levels on an XOI Alone. (Aug 2017-Feb 2019). Role: Sub-Investigator.

A Randomized, Double-Blind Placebo Controlled Study to access the effects of XXX on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant. **Phase 3**. Role: Sub- Investigator. (Oct 2018-Present)

A Randomized, Double-Blind Placebo Controlled, Parallel-group, Multicenter, Dose-Ranging Study to evaluate the Safety and Efficacy of XXX in Severely Obese Patients with Type 2 Diabetes Mellitus. **Phase 2**. Role: Sub Investigator. (May 2018-2019)

A **Phase 3**, multi-center, multi-national, placebo controlled, randomized, double-blind 26 week study to access the safety and efficacy of XXX in patients with severe hypertriglyceridemia.Role: Sub Investigator. (April 2018-2020)

An integrated assessment of safety and effectiveness of XXX for the management of essential hypertension (2017-2019). Role: Sub-Investigator

A **Phase 3**, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the analgesic efficacy and safety of a dose titration regiment for the subcutaneous administration of XXX in subjects with osteoarthritis of the hip of knee. (2016-2018). Role- Sub-Investigator.

A **Phase 2A**, Randomized, Double-Blind, Placebo Controlled crossover study of the Safety and Efficacy of XXX in subjects with Osteoarthritis of the knee. (2016-2016). Role- Sub-Investigator

A **Phase 3**, Randomized Withdrawal Double Blind Study of XXXX Monotherapy Compared to XXXX Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis. (2015-2018). Role- Joint Count Assessor

A **Phase 3**, Multi-Center Double-Blind, Randomized Controlled Study of XXXX and XXXX in Combination or as Monotherapy in Subjects with Psoriatic Arthritis. (2015-2017). Role- Joint Count Assessor

A **Phase 3B**, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of XXXX SC in Combination with XXXX Compared to XXX Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are XXXX Naïve. (2015-p2018). Role- Joint Count Assessor

Efficacy, Safety, and Immunogenicity of XXXX versus XXXX in patients with Active Rheumatoid Arthritis: A Randomized , Double-blind, Parallel-arm, Multiple Dose, Active Comparator. **Phase 3. (2015-2018). Role: Joint Count Assessor.**

Prospective, Multicenter, Single Arm Pilot Clinical Investigation Evaluating the use of a Surface Bleeding Severity Scale and the Safety and Efficacy of a new hemostatic **device** in abdominal and orthopedic lower extremity surgeries. (2015-2016). Role: Sub-Investigator

Prospective, Multi-Center, Randomized, Three–Arm, Parallel group, clinical study to evaluate the superiority of 3 weekly intra-articular doses of 2ml of Investigational Product as compared to Placebo and XXXX injected into the target knee for the treatment of pain in subjects with Osteoarthritis. (2015). **Device Study. Role: Sub-Investigator**

Double Blind, Placebo-controlled, Randomized, Parallel–group Study to Determine the Safety and Efficacy of a Topical Patch (XXXX) Following Daily Administration for 2 Weeks in Patients with Chronic Low Back Pain. **Phase 2.** (2015-2015) Role: Sub-Investigator

A Randomized, Sham-Controlled Pilot Study of XXXX Therapy in the Treatment of Persistent Post-Operative Pain following a Total Knee Arthroplasty (**Device Study**). (2015-2016). Role: Sub-Investigator

A Multicenter, Randomized, Sham-Controlled, Double-Blind Study of XXXX Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Discectomy (Device Study). Role: Sub-Investigator

A **Phase 3**, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of XXX, XXX, XXX, XXX in Subjects with Gout. (2014-2016). Role: Sub-Investigator

A, Double-blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of XXXX for the Treatment of Pain in Patients with Osteoarthritis of the Knee. (2014-2015). Role: Sub-Investigator

A Randomized, Double-Blind, Placebo-Controlled **Phase 3** Study to Evaluate the Efficacy, Safety, and Effect on Radiographic Progression of XXXX in Subjects with Psoriatic Arthritis. (2014-2015). Role: Joint Count Assessor.

A Multicenter, Randomized, Double-Blind, Parallel, Active Controlled Non-Inferiority Clinical Trial Comparing Three Weekly Intra-Articular Injections of XXXX Versus Three Weekly Intra-Articular Injections of XXX for the Treatment of Osteoarthritis Pain of the Knee. (2014-2015). Role: Sub Investigator. **(Device Study)**

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of a single intra-articular injection of XXX in adults with pain due to osteoarthritis of the knee. (1/2014- 10/2014). Role- Sub-Investigator.

A Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of XXX for the Treatment of Adhesive Capsulitis of the Shoulder. (12/2013-11/2014)
Role: Sub-Investigator.

Placebo Controlled, Double Blind Evaluation of the Efficacy and Safety of XXX for the treatment of Ankle Sprain. (Nov. 2013-2015). Role: Sub Investigator.

Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Worldwide, Proof of Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXX in Subjects with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Therapy. (May 2013-October 2013). Role: Joint Assessor

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of intra-articular injection of XXX in adults with pain due to osteoarthritis of the knee. (April 2013-August 2013). **Phase 2**. Role- Sub-Investigator.

A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Active Controlled, Parallel Group, Multicenter Trial of XXX to Assess the Analgesic Efficacy and the Management of Opioid Induced Constipation in Subjects with Moderate to Severe Chronic Low Back Pain and a history of OIC. (November 2012-2015).

A Randomized, Double-Blind, Multicenter, Placebo Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and YYY compared to YYY Alone in Lowering Serum Uric Acid and Resolving Tophi in Subjects with Tophaceous Gout. **Phase 3.**
(March 2012- Ext Study 2015). Role- Sub-Investigator

A Randomized, Double-Blind, Multicenter, Placebo Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and YYY compared to YYY Alone in Subjects with Gout who had an inadequate hypouricemic response to Standard of Care YYY. **Phase 3.**
(March 2012- Extension Study 2015). Role- Sub-Investigator

A Randomized, double Blind, active controlled study of XXX prefilled syringes or XXX reconstituted lyophilizate or YYY for treating acute gouty arthritis flares in frequently flaring patients. **Phase 3**. (5/2011- 2013)

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of XXX vs placebo on Renal Function in Gout Subjects with Hyperuricemia and Moderate to Severe Renal Impairment. **Phase 2.** (4/2011-2012)

A Multicenter, Randomized, Active Control, Phase 3B Study to Evaluate the Cardiovascular Safety of XXX and YYY in Subjects with Gout and cardiovascular Comorbidities. **Phase 3B.** Role: Sub-Investigator. (3/2011-2017)

A randomized, controlled study of xxx on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDS and/or colchicine are contraindicated, not tolerated or ineffective. **Phase 3**. Role: Sub-Investigator. (2010-2013).

A Randomized, Double-Blind, Multicenter, 2 Period, Crossover Study to Establish the Dose Equivalence and Direct Conversion Between Immediate Release (IR) and Extended Release (ER) XXX in Subjects with Moderate-to-Severe, Chronic Low Back Pain.

A Randomized, Open Label, Blinded Endpoint, Parallel Group Trial of GI safety of XXX compared with NSAIDS in Osteoarthritis Patients. (2007-2010). **Phase 4.**

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing XXX with YYY and ZZZ. (2006-2016). **Phase 4.** Role: Sub-Investigator.

A Six Week Double-Blind, Randomized, Multi-Center Comparison Study of the Analgesic Effectiveness of XXX compared to YYY in Subjects with Chronic Low Back Pain. (2006-April 2007). Role: Sub-Investigator.

Multinational, Multi-center, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study Assessing the Efficacy of Intravenous XXX in Preventing Subsequent Osteoporotic Fractures after a Hip Fracture. (2002- Feb. 2007). Role: Sub-Investigator.

Multicenter, Double-Blind, Placebo controlled, Randomized, Parallel Group Study to Compare the Efficacy and Tolerability of XXX vs. YYY in Treatment of Acute Ankle Sprains. (2002-2003). Role: Sub-Investigator.

A Randomized, Double-Blind, Active-comparator controlled, Parallel Group study to evaluate the safety of XXX in patients with Osteoarthritis Or Rheumatoid Arthritis. (2002-2006). Role: Sub-Investigator.

LISTING OF SECURITY FEATURES ON REVERSE SIDE

COMMONWEALTH OF VIRGINIA

DEPARTMENT OF HEALTH PROFESSIONS

David E. Brown, D.C., Director

William L. Harp, MD
Executive Director
(804) 367-4600

BOARD OF MEDICINE

9960 Mayland Drive, Suite 300
Henrico, VA 23233-1463
www.dhp.virginia.gov/medicine

License to Practice As A Physician Assistant

Bobby L. White

Issued
05/18/2000

Number
0110001158

To verify the status of this license, visit our website www.dhp.virginia.gov, which is a primary source verification of the credential issued by the Commonwealth of Virginia. To file a complaint about a licensee call: 1-800-533-1560.